Stockscreener 앱 받기
1.25
3.85%
-0.05
시간 외 거래:
1.27
0.02
+1.60%
전일 마감가:
$1.30
열려 있는:
$1.3
하루 거래량:
1.33M
Relative Volume:
0.51
시가총액:
$102.77M
수익:
$78.12M
순이익/손실:
$-153.22M
주가수익비율:
-0.6098
EPS:
-2.05
순현금흐름:
$-136.90M
1주 성능:
-4.58%
1개월 성능:
-13.79%
6개월 성능:
-69.59%
1년 성능:
-82.42%
1일 변동 폭
$1.24
$1.32
1주일 범위
$1.22
$1.40
52주 변동 폭
$1.12
$11.58
Editas Medicine Inc Stock (EDIT) Company Profile
명칭
Editas Medicine Inc
전화
617-401-9000
주소
11 HURLEY ST., CAMBRIDGE, MA
EDIT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
1.25 | 102.77M | 78.12M | -153.22M | -136.90M | -2.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.23 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-16 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-12-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-13 | 다운그레이드 | Truist | Buy → Hold |
| 2024-12-11 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-11-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-11-04 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-05-09 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-10-18 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | 업그레이드 | Stifel | Hold → Buy |
| 2023-06-12 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-13 | 개시 | Citigroup | Neutral |
| 2022-12-06 | 재개 | Credit Suisse | Neutral |
| 2022-11-18 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-09-29 | 개시 | BofA Securities | Neutral |
| 2021-10-19 | 개시 | SVB Leerink | Mkt Perform |
| 2021-09-24 | 개시 | Stifel | Hold |
| 2021-09-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-08-09 | 업그레이드 | Truist | Hold → Buy |
| 2021-08-05 | 업그레이드 | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | 개시 | Goldman | Sell |
| 2021-03-22 | 개시 | Credit Suisse | Outperform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-26 | 다운그레이드 | Truist | Buy → Hold |
| 2021-01-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | 개시 | Robert W. Baird | Underperform |
| 2020-06-18 | 재개 | SunTrust | Buy |
| 2020-02-21 | 개시 | Wells Fargo | Equal Weight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-10-10 | 개시 | Guggenheim | Neutral |
| 2018-09-21 | 개시 | Raymond James | Outperform |
| 2018-05-15 | 재확인 | Chardan Capital Markets | Buy |
| 2018-02-13 | 개시 | CLSA | Underperform |
| 2018-01-23 | 업그레이드 | SunTrust | Hold → Buy |
| 2017-07-14 | 개시 | SunTrust | Hold |
| 2017-03-28 | 개시 | Chardan Capital Markets | Buy |
| 2016-08-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-06-02 | 개시 | Jefferies | Hold |
| 2016-02-29 | 개시 | JMP Securities | Mkt Outperform |
| 2016-02-29 | 개시 | JP Morgan | Neutral |
| 2016-02-29 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Editas Medicine Inc 주식(EDIT)의 최신 뉴스
Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Up 7.6% in January - MarketBeat
Cancer Gene Therapy Market Growth, and Forecast through - openPR
Editas Medicine, Inc. to Host Earnings Call - ACCESS Newswire
Top 5 CRISPR Companies To Invest In (February 2025) - Securities.io
Leerink Partnrs Comments on Editas Medicine FY2025 Earnings - MarketBeat
FY2024 EPS Estimate for Editas Medicine Decreased by Analyst - MarketBeat
Brokers Offer Predictions for Editas Medicine FY2025 Earnings - MarketBeat
Beta Thalassemia Market on Track for Major Expansion by 2034, According to DelveInsight | Agios Pharma, Vertex Pharma, Pharmacosmos, Editas Medicine, HemaQuest Pharma, Acceleron Pharma, Bristol-Myers - Barchart
Beta Thalassemia Market on Track for Major Expansion by 2034, - openPR
Analysts Issue Forecasts for Editas Medicine FY2025 Earnings - MarketBeat
Hennion & Walsh Asset Management Inc. Has $340,000 Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
JPMorgan Chase & Co. Decreases Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of “Hold” by Brokerages - Defense World
Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Update - MarketBeat
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential (NASDAQ:EDIT) - Seeking Alpha
Editas Medicine, Inc. (NASDAQ:EDIT) Stock Position Lifted by Barclays PLC - Defense World
CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers - Seeking Alpha
International Assets Investment Management LLC Trims Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
Editas, after slow start, outlines plan to catch other CRISPR companies - STAT
Editas Medicine stock hits 52-week low at $1.16 amid steep decline - Investing.com Australia
Editas Medicine Outlines 2025 Strategic Priorities and Milestones - Yahoo Finance
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Yahoo Finance
Editas Medicine stock hits 52-week low at $1.16 amid steep decline By Investing.com - Investing.com South Africa
CRISPR-based Gene Editing Market Report 2025, with Company Profiles of the Top 10+ Major Market Players - Yahoo Finance UK
Editas Medicine advances gene editing treatments - Investing.com
Editas Medicine (EDIT) Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities - StreetInsider.com
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities - The Manila Times
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key - The Bakersfield Californian
Editas Medicine Highlights New In Vivo Preclinical Proof of - GlobeNewswire
Editas Medicine Achieves Major Gene Editing Breakthrough in Primate Study, Sets 2027 Roadmap - StockTitan
Intellia, citing 'challenging market environment,' lays off 27% of staff as it takes ax to pipeline - Fierce Biotech
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Editas Medicine To Present At The 43rd Annual J.P. Morgan Healthcare Conference - Barchart
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Editas Medicine CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Geode Capital Management LLC Lowers Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Up 5.4% in December - Defense World
Short Interest in Editas Medicine, Inc. (NASDAQ:EDIT) Increases By 5.4% - MarketBeat
Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
Top 11 CRISPR Stocks to Invest In - Insider Monkey
State Street Corp Cuts Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by State Street Corp - Defense World
Editas Medicine, Inc. (NASDAQ:EDIT) Receives $7.00 Average PT from Brokerages - MarketBeat
Editas Medicine (STU:8EM) Cyclically Adjusted FCF per Share : €-1.69 (As of Sep. 2024) - GuruFocus.com
Editas Medicine stock plunges to 52-week low of $1.27 - Investing.com
Cambridge company is laying of 180 people, 65% of its workforce - MSN
Editas Medicine's SWOT analysis: gene editing firm pivots strategy amid stock uncertainty - Investing.com
Editas to cut 65% of workforce in strategy shift; shelves lead gene-editing program - MSN
Editas Medicine announces CMO departure and transition plan - Investing.com
Editas Medicine Inc (EDIT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Editas Medicine Inc 주식 (EDIT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mei Baisong | EVP, CHIEF MEDICAL OFFICER |
Dec 03 '24 |
Sale |
2.08 |
541 |
1,124 |
133,354 |
| Mei Baisong | EVP, CHIEF MEDICAL OFFICER |
Sep 04 '24 |
Sale |
3.42 |
518 |
1,774 |
133,895 |
| O'Neill Gilmore Neil | CEO |
Sep 04 '24 |
Sale |
3.42 |
1,555 |
5,325 |
313,724 |
1.09%
자본화:
|
볼륨(24시간):